Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

A Look at Cannabis Extracts for Patients with Chronic Lymphocytic Leukemia

Web Exclusives

Cannabis has been used for centuries for both medicinal and recreational purposes, and recent studies have suggested that its active compounds, called cannabinoids, may have anticancer benefits.1,2

Inside the body, cannabinoids function by binding to specialized cannabinoid receptors on the outside of cells.2 Cannabinoid receptors are commonly found in the brain and on cells of the immune system but have also been found in high quantities in both solid tumors and cancers of the blood.2 Interestingly, exposing cancer cells to cannabinoids in a laboratory has been shown to inhibit their ability to move, grow, divide, and produce new blood vessels—crucial features for a cancer cell.2

In a 2016 study, researchers found that chronic lymphocytic leukemia (CLL) cells have high quantities of cannabinoid receptors,2 but were unable to show that adding synthetic cannabinoids alone to CLL cells could significantly reduce their viability or ability to migrate.2 However, subsequent studies have shown that using natural cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), can have anticancer activity in leukemia cells.3 Notably, the ability to kill leukemia cells was improved when cannabinoids were used together, and an even stronger effect was seen when cells were treated with cannabinoids at the same time or right after having received chemotherapy.3

Although these findings are promising, it is important to remember that there is a lack of human clinical trials in this area.1 Cannabis extracts containing CBD, which by itself does not cause the “high” associated with THC, have a complicated legal status in the United States; all 50 states have legalized CBD, with some restrictions, whereas the federal government still considers it illegal but has refrained from enforcement.4

This means that CBD is generally available to individuals across the country, and often without a prescription. Because CBD is primarily marketed as a supplement, and not a medication, the US Food and Drug Administration does not regulate its safety or purity.4 Those considering using CBD should exercise caution, however. There are currently no regulations to ensure that the product they buy contains the active ingredients listed on the label.4 Furthermore, the CBD products could also contain other, unknown components.4 Finding the right dose of CBD can also be a challenge due to the absence of high-quality clinical studies, so individuals will have to experiment to find what works for them.1,4

The good news is that CBD is generally considered safe, although it can cause nausea, fatigue, irritability, dry mouth, and changes in appetite in some people.1,4 There is also a risk that CBD could interfere with other medications, so it is important to speak with your doctor before starting to take CBD, or any other nutritional or medicinal supplement.1,4


References

  1. Ashton L. CBD oil for leukemia: benefits, effects & how to use. Center for Advancing Health. Published January 9, 2021. www.cfah.org/cbd-oil-for-leukemia. Accessed March 19, 2021.
  2. Freund P, Porpaczy EA, Le T, et al. Cannabinoid receptors are overexpressed in CLL but of limited potential for therapeutic exploitation. PLoS One. 2016;11:e0156693.
  3. Scott KA, Dalgleish AG, Liu WM. Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. Int J Oncol. 2017;51:369-377.
  4. Grinspoon P. Cannabidiol (CBD) - what we know and what we don’t. Harvard Health Blog. Published August 24, 2018. www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476. Accessed March 19, 2021.

Recommended For You